TLR4 and hepatitis B virus infection: Monophosphoryl lipid A, a chemically modified product of LPS, was the first TLR4 agonist approved for use in human vaccines, and it is currently included in CervarixTM, a vaccine for human papillomavirus (HPV) and FENDrixTM, a vaccine for hepatitis B (75).